financetom
Business
financetom
/
Business
/
Booz Allen Hamilton Raises Full-Year Earnings Outlook Following Surprise Quarterly Profit Increase
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Booz Allen Hamilton Raises Full-Year Earnings Outlook Following Surprise Quarterly Profit Increase
Mar 11, 2026 1:30 AM

09:07 AM EST, 01/23/2026 (MT Newswires) -- Booz Allen Hamilton ( BAH ) raised its full-year earnings outlook on Friday as the technology and management consulting firm's bottom line unexpectedly increased year over year in the fiscal third quarter.

The company now anticipates adjusted earnings to be in a range of $5.95 to $6.15 per share for fiscal 2026, up from its previous projections of $5.45 to $5.65. The current consensus on FactSet is for non-GAAP EPS of $5.62. The stock advanced 6.7% in the most recent premarket activity.

"We expect quarter four funding to improve over quarter three, but remain slower than usual," Chief Operating Officer Kristine Anderson said during an earnings call, according to a FactSet transcript. "We will continue running the business effectively and efficiently."

Revenue is pegged at $11.3 billion to $11.4 billion for the ongoing fiscal year, compared with the prior guidance of $11.3 billion to $11.5 billion, reflecting "some of the impacts from the prolonged government shutdown," according to Anderson. The revised forecast reflects an annual decline of 5% to 6%, compared with previous estimates for a decrease of 4% to 6%. The Street is looking for $11.4 billion.

Booz Allen reported adjusted EPS of $1.77 for the December quarter, up from $1.55 the year before, defying the average analyst estimate for a drop to $1.29. However, revenue fell 10% to $2.62 billion, below the Street's view for $2.75 billion. Excluding billable expenses, revenue declined 6.7% to $1.85 billion.

The record-long federal government shutdown, which ended in November, impacted the company's revenue in the quarter, Chief Financial Officer Matt Calderone said on the call. "We lost some revenue due to work not performed and we also saw some revenue push from (the third quarter) to (the fourth quarter) given timing delays and billable expenses," according to Calderone.

Defense revenue remained nearly flat at $1.45 billion, while civil slipped to $732 million from $1.01 billion last year. Intelligence revenue decreased to $434 million from $452 million in the prior-year quarter.

"We successfully navigated through both the government shutdown and significant cost actions in the quarter," Calderone told analysts. "The shutdown pushed some procurements and funding actions to the right."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Glenfarne seeks five more years until 2029 to build Texas LNG export plant
Glenfarne seeks five more years until 2029 to build Texas LNG export plant
May 28, 2024
May 28 (Reuters) - U.S. energy company Glenfarne Group LLC has asked federal energy regulators for five more years until November 2029 to put its proposed Texas LNG export plant in Texas into service, according to a filing made available on Tuesday. Texas LNG is one of more than three dozen LNG export plants being developed in the U.S., Mexico...
Hess shareholders approve merger with Chevron
Hess shareholders approve merger with Chevron
May 28, 2024
HOUSTON (Reuters) - Hess Corp ( HES ) on Tuesday approved the company's $53 billion merger with the No. 2 U.S. oil company Chevron ( CVX ), according to preliminary results of the vote. The merger required a majority vote to approve the deal by a majority of Hess' 308 million shares outstanding to pass. The company did not immediately...
Why Is AstraZeneca Stock Trading Lower On Tuesday?
Why Is AstraZeneca Stock Trading Lower On Tuesday?
May 28, 2024
On Tuesday, AstraZeneca Plc ( AZN ) said the survival results did not reach statistical significance in the overall trial population in the TROPION-Lung01 phase 3 trial. Topline overall survival (OS) results from the TROPION-Lung01 phase 3 trial, which previously met the dual primary endpoint of progression-free survival (PFS), numerically favored datopotamab deruxtecan (Dato-DXd) compared to docetaxel for locally advanced or metastatic non-small cell lung cancer (NSCLC)...
Hess Shareholders Approve Takeover by Chevron
Hess Shareholders Approve Takeover by Chevron
May 28, 2024
02:37 PM EDT, 05/28/2024 (MT Newswires) -- Hess (HES) said Tuesday it obtained shareholders' approval at a special meeting to its acquisition by Chevron. The completion of the merger transaction is still subject to other closing conditions, the company said. Hess shares were down 0.2% in recent Tuesday trading, while Chevron stock was up 0.6%. Price: 150.99, Change: -0.40, Percent...
Copyright 2023-2026 - www.financetom.com All Rights Reserved